Cybin Secures Patent for Novel Phenethylamines Program, Expanding its CNS Disorder Research
Cybin Inc., a leading psychedelic medicine company, has achieved a significant milestone in its research and development efforts. The United States Patent and Trademark Office (USPTO) has granted U.S. patent 12,122,741, covering the composition of matter for lead preclinical candidates within Cybin’s CYB005 phenethylamines program. This program explores the potential of novel molecules, administered at non-hallucinogenic doses, to treat Central Nervous System (CNS) disorders.
The grant of this patent signifies Cybin’s dedication to expanding its research beyond its existing clinical tryptamine programs. The company is actively exploring the potential of non-hallucinogenic neuroplastogens within its broader discovery pipeline, including targeted serotonin 5-HT1A and 5-HT2Creceptor agonists.
“The granting of this patent in support of our CYB005 phenethylamines program reinforces our commitment to expanding the breadth of innovative development work beyond our clinical tryptamine programs,” said Doug Drysdale, CEO of Cybin. “Non-hallucinogenic 5-HT receptor agonists have garnered a great deal of attention in recent years, and we are eager to continue exploring their clinical potential in CNS disorders. While our primary focus remains on our clinical-stage psychiatry programs, CYB003 and CYB004, we believe that other programs like CYB005 that target CNS disorders have the potential to address significant unmet medical needs.”
In August, Cybin held a Type B Initial Breakthrough Therapy Meeting with the FDA and revealed its plans to initiate a Phase 3 pivotal trial of CYB003 for the adjunctive treatment of major depressive disorder in late summer of 2024. The company anticipates 12-month efficacy results from its Phase 2 study of CYB003 in major depressive disorder in the fourth quarter of 2024.
Cybin’s commitment to innovation is further reflected in its July acquisition of U.S. patent no. 12,042,564. This patent provides additional protection for the CYB004 program, currently under development for Generalized Anxiety Disorder (GAD).
The company’s ongoing research and development efforts, coupled with its recent patent acquisitions, demonstrate its dedication to developing innovative therapies for a wide range of CNS disorders. Cybin’s focus on non-hallucinogenic approaches, combined with its commitment to rigorous clinical trials, positions the company as a leader in the emerging field of psychedelic-assisted therapies.